Saturday 17 October 2026
Export ALPS’s income statement to Excel — free account
Alps Group Inc.
ALPS Healthcare Biotechnology
Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025. In the quarter to September 2025, EPS fell 609.4% and free cash flow fell 26.5%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow ALPS
| Mar '26 | Sep '25 | Jun '25 | Mar '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
— | 0.04 | 0.25 | 0.01 |
+8 more quarters Free account |
Net Debt/EBITDA |
— | 5.50 | (0.31) | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.30 | 0.30 | 0.22 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | (1.00) | (0.70) | (1.12) | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | (0.07) | (0.08) | (0.05) | |
Cash per Share |
— | 0.10 | 0.01 | 0.00 | |
Shareholders Equity per Share |
— | (3.53) | (3.40) | (3.09) | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
— | (3.53) | (3.40) | (3.09) | |
Free Cash Flow |
— | (0.25) | (0.27) | (0.16) | |
Working Capital |
— | (8.55) | (7.86) | (6.79) | |
Net Current Asset Value |
— | (13.53) | (12.84) | (14.21) | |
| Other line items | |||||
Quick Ratio |
— | 0.04 | 0.00 | 0.00 | |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
— | (0.07) | (0.08) | (0.05) | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Average Payables |
— | 0.14 | 0.13 | 0.08 | |
Average Assets |
1.85 | 15.84 | 16.68 | 16.40 | |
Average Common Equity |
— | (10.71) | (10.23) | (9.37) |
Columns are period end dates